{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:53Z","timestamp":1792712573177,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1053\/j.seminoncol.2022.01.012","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:03:55Z","timestamp":1644876235000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use"],"prefix":"10.1053","volume":"49","author":[{"given":"Ji Won","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-2380","authenticated-orcid":false,"given":"Jeong Uk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1053\/j.seminoncol.2022.01.012_bib0001","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2217\/fon-2017-0585","article-title":"Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer","volume":"14","author":"Anari","year":"2018","journal-title":"Future Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.012_bib0002","first-page":"4105","article-title":"Present and future of cancer immunotherapy: A tumor microenvironmental perspective","volume":"16","author":"Yu","year":"2018","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.012_bib0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.012_bib0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.012_bib0006","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.012_bib0007","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.012_bib0008","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/1759-7714.13405","article-title":"Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events","volume":"11","author":"Zheng","year":"2020","journal-title":"Thoracic cancer"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","author":"G\u00e9rard","year":"2021","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574271","article-title":"The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Frontiers in immunology"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.012_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.012_bib0012","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney international reports"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.012_bib0013","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.012_bib0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney international reports"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.012_bib0015","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1002\/cnr2.1250","article-title":"Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?","volume":"3","author":"Vaughan","year":"2020","journal-title":"Cancer reports (Hoboken, NJ)"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0016","article-title":"Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity","author":"Sorah","year":"2020","journal-title":"Journal of immunotherapy (Hagerstown, Md: 1997)"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.012_bib0017","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney international reports"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.012_bib0018","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clinical and experimental nephrology"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.012_bib0019","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"10.1053\/j.seminoncol.2022.01.012_bib0020","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.012_bib0021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.21873\/anticanres.13175","article-title":"Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution","volume":"39","author":"Sukari","year":"2019","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.012_bib0022","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.012_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.012_bib0026","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cpt.982","article-title":"Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status","volume":"103","author":"Baverel","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.012_bib0027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/cpt.587","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma","volume":"102","author":"Stroh","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.012_bib0028","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.012_bib0029","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.012_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12132","article-title":"Using Model-Based \"Learn and Confirm\" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial","volume":"6","author":"Elassaiss-Schaap","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.012_bib0031","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.012_bib0032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.12323","article-title":"Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma","volume":"78","author":"Feng","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.012_bib0033","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.012_bib0034","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10637-018-0673-y","article-title":"Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review","volume":"37","author":"Cheun","year":"2019","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.012_bib0035","doi-asserted-by":"crossref","first-page":"e903","DOI":"10.1016\/j.clgc.2019.06.009","article-title":"Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature","volume":"17","author":"Vitale","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.012_bib0036","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.012_bib0037","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: a case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.012_bib0038","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-137-9-200211050-00010","article-title":"Diagnosis and treatment of acute tubular necrosis","volume":"137","author":"Esson","year":"2002","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.012_bib0039","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.ajkd.2018.12.029","article-title":"Renal Imaging: Core Curriculum 2019","volume":"73","author":"Fried","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1053\/j.seminoncol.2022.01.012_bib0041","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.012_bib0042","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0043","first-page":"2016","article-title":"Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis","author":"Chang","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"15_suppl","key":"10.1053\/j.seminoncol.2022.01.012_bib0044","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14553","article-title":"Anti-PD-1 therapy in patients with end-stage renal disease on dialysis: A single-center case series","volume":"35","author":"Park","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.seminoncol.2022.01.012_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/CMAR.S73389","article-title":"Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease","volume":"7","author":"Cavalcante","year":"2015","journal-title":"Cancer Manag Res"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:56:43Z","timestamp":1758805003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0093775422000124"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.012","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}